Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | GABRP | O00591 | 1/20 | 0.74 |
| ▸ | GABRD | O14764 | 1/20 | 0.74 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.74 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.74 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.74 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.74 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.74 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.74 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.74 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.74 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.74 |
| ▸ | GABRE | P78334 | 1/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.74 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.74 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.74 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.74 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.74 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isonipecotic Acid SCHEMBL29651431 | 1.00 | TSHR (0.74) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Trifluoroacetic Acid SCHEMBL13738487 | 0.88 | SLC6A1 (0.59) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Trifluoroacetic Acid SCHEMBL1609057 | 0.88 | SLC6A1 (0.59) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Trifluoroacetic Acid SCHEMBL13738318 | 0.88 | SLC6A1 (0.59) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Trifluoroacetic Acid SCHEMBL23466638 | 0.87 | GABRP (0.54) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Isonipecotic Acid SCHEMBL104297 | 0.86 | — | — | |
| Isonipecotic Acid SCHEMBL2027408 | 0.86 | TSHR (1.00) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Isonipecotic Acid SCHEMBL28266161 | 0.84 | TSHR (0.85) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Isonipecotic Acid SCHEMBL5035880 | 0.84 | TSHR (0.94) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Isonipecotic Acid SCHEMBL1703706 | 0.84 | TSHR (0.94) | TSHRGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12521393-B2 | Cytotoxicity targeting chimeras for CCR2-expressing cells | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-13 | — | — | US | disclosed |
| EP-4640280-A2 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| EP-4384223-B1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-10-01 | — | — | EP | disclosed |
| CN-115925697-B | Small molecule immunoregulation inhibitor and pharmaceutical composition and application thereof | 昆药集团股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250136722-A1 | CYTOTOXICITY TARGETING CHIMERAS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| US-20240325392-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| EP-4384224-A1 | CYTOTOXICITY TARGETING CHIMERAS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| CN-115925697-A | Small molecule immunoregulation inhibitor and pharmaceutical composition and application thereof | 昆药集团股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-9585881-B2 | Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160287582-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-06 | — | — | US | disclosed |
| CN-105934435-A | 2-amino-6-fluoro-N- [ 5-fluoro-pyridin-3-yl ] pyrazolo [1, 5-a ] pyrimidine-3-carboxamide compounds as ATR kinase inhibitors, their preparation, different solid forms, and radiolabeled derivatives thereof | 沃泰克斯药物股份有限公司 | 2016-09-07 | — | — | CN | disclosed |
| EP-3056493-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-9394250-B2 | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20150152048-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2855452-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO Pharmaceutical Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013174937-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD (JP) | 2013-11-28 | — | — | WO | disclosed |
| CN-101448835-B | 6,7,8, 9-tetrahydro-5H-pyrimido [4,5-D ] azepin-4-yl ] -amine derivatives as TRPV1 modulators for the treatment of pain | JANSSEN PHARMACEUTICA NV | 2012-06-27 | — | — | CN | disclosed |
| CN-101448835-A | 6 as TRPV1 modulators for the treatment of pain | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287582-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | TSHR 2604/4885GABRP 3123/4885GABRD 4422/4885 |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | TSHR 778/4885GABRP 2233/4885GABRD 2447/4885 |
| US-20150152048-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | TSHR 2604/4885GABRP 3123/4885GABRD 4422/4885 |
| US-20250136722-A1 | CYTOTOXICITY TARGETING CHIMERAS | HAVCR2, CD47, CYTH3 | TSHR 1405/4885GABRP 1472/4885GABRD 2303/4885 |
| US-20240325392-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | TSHR 1629/4885GABRP 2143/4885GABRD 2279/4885 |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | TSHR 2972/4885GABRP 442/4885GABRD 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.